Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically\* or cytologically confirmed colorectal adenocarcinoma~  * No other cellular type (e.g., sarcoma, lymphoma, or carcinoid) NOTE: \*If the primary colorectal tumor and the hepatic lesions have been identified at the same time and it is not possible to biopsy the colorectal lesion, the patient will be eligible without histologic confirmation of the colorectal primary cancer as long as other radiographic studies or scans document the characteristics of a colorectal cancer~* Synchronous or metachronous metastatic disease confined to the liver~  * No more than 6 hepatic metastatic lesions that can potentially be resected or ablated~ * For patients presenting with synchronous lesion(s) in the colon and/or rectum, the primary tumors must, in the opinion of the investigator, appear to be completely resectable~* Must be able to undergo surgery and/or ablation within 28 days following randomization~* No evidence of extrahepatic metastases~* No prior colorectal metastases~* No recurrent colorectal cancer concurrent with hepatic metastases~PATIENT CHARACTERISTICS:~* Life expectancy ≥ 5 years, excluding their colorectal cancer~* Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status 0-1~* No other malignancy within the past 5 years except carcinoma in situ of the cervix, melanoma in situ, basal cell or squamous cell skin cancer, or carcinoma of the colon or rectum~* Absolute granulocyte count ≥ 1,200/mm\^3~* Platelet count ≥ 100,000/mm\^3~* PT/international normalized ratio (INR) ≤ 1.5 unless patient is on therapeutic doses of anticoagulant medication~* Total bilirubin ≤ upper limit of normal (ULN)~* Alkaline phosphatase ≤ 2.5 ULN~* aspartate aminotransferase (AST) ≤ 2.5 times ULN~* Calculated creatinine clearance \> 50 mL/min~* Not pregnant or lactating~* Negative pregnancy test~* Patients with child bearing potential must agree to use adequate contraception~* Able to swallow oral medication~* No preexisting chronic hepatic disease (e.g., chronic active hepatitis or cirrhosis)~* No grade 3 or 4 anorexia or nausea~* No vomiting ≥ grade 2~* No clinically significant peripheral neuropathy defined as ≥ grade 2 neurosensory or neuromotor toxicity~* No psychiatric or addictive disorders or other condition that, in the opinion of the investigator, would preclude study participation~PRIOR CONCURRENT THERAPY:~* Prior adjuvant fluorouracil alone or in combination with levamisole, leucovorin calcium, irinotecan hydrochloride, or oxaliplatin allowed if these regimens were completed \> 6 months ago~* No prior resection/ablation, hepatic arterial infusion therapy, or any systemic chemotherapy for metastatic disease~  * Prior excisional biopsy allowed~* No prior radiotherapy to the liver~* No concurrent bevacizumab in patients who have had pump/catheter placement receiving hepatic arterial infusion of floxuridine~  * Patients who meet specific situations outlined in the protocol and who have not had pump placement may receive bevacizumab at the physician's discretion~* No concurrent halogenated antiviral agents such as sorivudine or brivudine in patients receiving fluorouracil, floxuridine, or capecitabine~* No concurrent filgrastim (G-CSF), pegfilgrastim, or sargramostim (GM-CSF) as primary prophylaxis for neutropenia~  * Following neutropenic events, these drugs may be used at the physician's discretion during subsequent cycles~* No other concurrent cancer therapy~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Capecitabine + Oxaliplatin (Type: ACTIVE_COMPARATOR): Within 4-6 weeks after surgery and/or ablation, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity.
- Arm 2: Floxuridine + Oxaliplatin + Capecitabine (Type: EXPERIMENTAL): Within 4-6 weeks after surgery and/or ablation, patients receive a continuous hepatic arterial infusion of floxuridine on days 1-14, oxaliplatin IV over 2 hours on day 22, and oral capecitabine twice daily on days 22-35. Treatment repeats every 42 days for 4 cycles in the absence of unacceptable toxicity. Beginning with cycle 5, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment with oxaliplatin and capecitabine repeats every 21 days for 4 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).